Supplement Table 1: List of PhD, Postdoctorates, senior clinicians, and investigators raised or having joined in the Inserm units and the Institute of Transplantation I headed. Only the year of arrival is indicated.

Buzelin Françoise, MD, 1976

Peyronnet Pierre, MD, 1976

Bignon Denis, Ph, PhD, 1978

Chatal Jean François, MD, PhD 1979

Ythier Arnaud, MD, PhD, 1979

Houssain Elisabeth, PhD 1979

Hourmant Maryvonne, MD, PhD 1980

Guyot Claude, MD, 1981

Moreau Jean François, MD, PhD 1982

Hallet Marie-Martine, PhD, 1982

Fiche Marise, MD, 1982

Godard Anne, Ph, PhD 1982

Chevalier Sylvie , PhD, 1982

Chailleux Edmond, MD, 1983

Jacques Yannick, PhD 1983

Vié Henri, PhD 1983

Bonneville Marc, Vet, PhD 1983

Le Mauff Brigitte, MD, PhD1983

Baatard Remy, MD, 1984

Gascan Hugues, PhD 1984

Dreno Brigitte, MD, PhD 1984

Moisant Jean-Paul, MD, PhD 1985

Chabannes Dominique, PhD, 1986

Paineau Jacques, MD, PhD, 1986

Karam Georges, MD, PhD1986

Boucho Olivier MD, PhD, 1987

Esnault Vincent, MD, PhD, 1987

Bugeon Laurence, PhD 1987

Anegon Ignacio, MD, PhD 1988

Bigot Edith, Ph,PhD, 1988

Dantal, Jacques, MD, PhD, 1988

Cantarovich Diego, MD, PhD, 1988

Giral Magali, MD, PhD, 1989

Breathnach Richard, PhD 1989

Josien Regis, MD, PhD, 1990

Blancho Gilles, MD, PhD, 1990

Cuturi Cristina, MD, PhD 1990

Nataf Serge, MD, PhD, 1991

Charreau Beatrice, PhD 1992

Parker Kay, PhD, 1992

Miranda Vincenzo, MD, PhD, 1992

Chevrier Dominique, PhD, 1992

Villers Daniel, MD, 1993

Bouhours Jean-François, PhD, 1994

Pourcel Christine, PhD 1994

Thibaudeau Karine, PhD, 1994

Sigalla Jeanne, PhD 1994

Borche Louis, PhD, 1994

Bogers Willie, PhD 1994

Buelow Richard, PhD, 1995

Sebille Fabien , PhD, 1996

Vignes Carole, PhD, 1997

Boulday Gewenaelle, PhD, 1997

Brouard Sophie, Vet, PhD, 1997

Bernard Vanhove, PhD, 1997

Le Berre Ludmilla, PhD , 1997

Coupel Stephanie, MD, PHD, 1998

Peche Hélène, PhD, 1998

Imbert Berthes –Marie, PhD, 1998

Van Denderen Brice, PhD, 1998

Petzold, Thomas, MD 1998

Melchior Benoist, PhD, 1999

Nagasaka Takahari, MD 1999

Brachet Philippe, PhD, 1999

Mai Hoa, MD, PhD, 2000

Guillet Marina, PhD, 2000

Breaudeau Cecile, PhD, 2000

Godfrin Yann, PhD, 2000

Gagne Katia, PhD 2000

Renaudin Karine MD, PhD 2000

Laplaud david, MD, PhD, 2001

Asthon-Chess Joanna, PhD, 2001

Degauque Nicolas, PhD, 2001

Bernardet Stephanie PhD, 2001

Moreau Anne, MD, 2001

Barreau Nathalie, PhD, 2001

Miqueu Patrick, PhD, 2002

Berthelot Laure, PhD, 2002

Lair David PhD, 2002

Ballet Caroline, PhD, 2003

Fang Chen, MD, 2003

Naveilhan Philippe, PhD, 2003

Foucher Yoann, PhD 2003

Louis Stephanie, PhD, 2003

Baeten Dominique, MD, PhD, 2004

Roussey Gwenaelle, MD, PhD, 2004

Braud Christophe, PhD, 2004

Racapé Maud, PhD, 2005

Jovanovic Voja, PhD, 2005

Dupont Alexandre, PhD, 2005

Michel Laure, MD, PhD, 2006

Dugast Emilie, PhD, 2006

Danger Richard, PhD, 2006

Vistoli Flavio, MD, 2006

Pettre, S, PhD, 2007

Bahbouhi B, PhD, 2007

Harb Jean Ph, PhD, 2007

Poirier Nicolas, MD 2007

Akl Ahmed, MD, 2008

Duong Van Huyen, MD, PhD, 2009

Salou Marion PhD, 2009

Bach Jean Marie, Vet, PhD 2009

Elong-Ngono, Annie, PhD, 2010

Conchon Sophie, PhD, 2011

Vabres Bertrand, MD, 2012

Salama Apolline, Vet, PhD, 2013

Couvrat-Desvergnes Gregoire, MD 2013

Table S2: Data presented during the 7th Histocompatibility Workshop organized by Walter, and Julia Bodmer, Oxford, 1977, and corresponding to the table 2 of the subsequent paper, showing an almost perfect fit between de novo post graft anti-Class II and steroid resistant rejection and graft failure. Reproduced from Soulillou JP, Peyrat MA, Guenel J. Association between treatmentresistant kidney-allograft rejection and post-transplant appearance of antibodies to donor B-lymphocyte alloantigens. *Lancet*. 1978;1:354–6.

TABLE II—GRAFT FUNCTION AND RECIPIENT'S ANTIBODY RESPONSE TO DRW ANTIGENS AND HLA ANTIGENS OF GRAFT DONOR

Patient no.	Graft function	Serum-creatinine (mg/l)	Antibodies to donor antigens	
			DRw	HLA
1	+	10·5	—	—
2	+	14·7	—	—
3	+	11·0	—	—
4‡	+	13·5	—	—
5	+	9·5	—	—
6	+	16·0	—	—
7	+	11·2	—	—
8	+	12·5	—	—
9	+	12·0	—	—
10	+	9·0	—	—
11	±	31·0	+++† *(10)**	—
12	±	34·0	++++ *(86)*	+ *(86)*
13	±	26·0	++++ *(18)*	—
14	—	..	++++ *(6)*	+ *(10)*
			++ *(4)*	—
15	—	..	++++ *(90)*	+ *(90)*
16	—	..	+++ *(120)*	—
17	—	..	+++ *(75)*	—
18	—	..	+++ *(30)*	—

*Number of days after transplantation when antibodies were first detected are shown in parentheses.

†Strength of the reaction: +=25% cells killed in cytotoxicity assay; ++=50%; +++=75%; ++++=100%.

‡Patient died of colonic perforation with a functional kidney graft 2½ months after transplantation.

Supplement Figure 1: The three major topics I studied (beside the miscellaneous one!), with the name of the closest collaborator for each of them. The symbolic background represents the molecular nodes of transcript profiling identified in the blood from operationally tolerant patients obtained with Sophie Brouard et al.



Tolerance (DST, first Medawar Avatar)



"Passive and active enhancement" in rats

Anti-MHC in HUMANS

DOGS

Operational tolerance

Sophie Brouard

B Reg

Biomarkers of Immune risk

XENO-Transplantation

Primate lab
G Blancho

GENETIC ENGINEERING
I Anegon



α1,3Gal, Neu5Gc-Double KO Pigs
C Galli

Xenothera Development

Xenome/ Translink
(EU FP7 Grants)
E Cozzi